keyword
https://read.qxmd.com/read/38128960/european-glaucoma-society-a-guide-on-surgical-innovation-for-glaucoma
#1
JOURNAL ARTICLE
Luis Abegao Pinto, Gordana Sunaric Mégevand, Ingeborg Stalmans
PROLOGUE: Glaucoma surgery has been, for many decades now, dominated by the universal gold standard which is trabeculectomy augmented with antimetabolites. Tubes also came into the scene to complement what we use to call conventional or traditional glaucoma surgery. More recently we experienced a changing glaucoma surgery environment with the "advent" of what we have become used to calling Minimally Invasive Glaucoma Surgery (MIGS). What is the unmet need, what is the gap that these newcomers aim to fill? Hippocrates taught us "bring benefit, not harm" and new glaucoma techniques and devices aim to provide safer surgery compared to conventional surgery...
December 21, 2023: British Journal of Ophthalmology
https://read.qxmd.com/read/37851966/a-proposal-for-the-use-of-a-fixed-low-energy-slt-for-open-angle-glaucoma
#2
JOURNAL ARTICLE
Sacks Zachary, Katz L Jay, Gazzard Gus, Sarah H Van Tassel, Eytan Z Blumenthal, Lerner S Fabian, Augusto Azuara-Blanco, Gregory John Roy Spooner, Yoram Solberg, Thomas Samuelson, Belkin Michael
Selective Laser Trabeculoplasty (SLT) has been in routine clinical use for over 20 years with millions of patients successfully treated and a low rate of clinically significant complications. The procedure requires the clinician to manually position the laser beam on the trabecular meshwork (TM) using a gonioscopy lens and to titrate the SLT laser energy based upon the amount of pigmentation in the angle as well as the observation of small bubbles produced by the laser effect. We propose that SLT energy titration is unnecessary either to achieve intraocular pressure (IOP) reduction nor to minimize potential side effects...
October 12, 2023: Journal of Glaucoma
https://read.qxmd.com/read/37742700/glaucoma-now-and-beyond
#3
REVIEW
Hari Jayaram, Miriam Kolko, David S Friedman, Gus Gazzard
The glaucomas are a group of conditions leading to irreversible sight loss and characterised by progressive loss of retinal ganglion cells. Although not always elevated, intraocular pressure is the only modifiable risk factor demonstrated by large clinical trials. It remains the leading cause of irreversible blindness, but timely treatment to lower intraocular pressure is effective at slowing the rate of vision loss from glaucoma. Methods for lowering intraocular pressure include laser treatments, topical medications, and surgery...
November 11, 2023: Lancet
https://read.qxmd.com/read/37390324/managing-primary-open-angle-glaucoma-in-the-setting-of-suboptimal-surgical-outcomes-in-the-fellow-eye
#4
JOURNAL ARTICLE
Marshall J Huang, Thomas W Samuelson, Ticiana De Francesco, Ariana Levin, Erin Sieck, Gus Gazzard, Matt Porter, Mark Gallardo, Robert T Chang, Wendy W Liu, Craig Chaya, Shawn Gulati, Manjool Shah
A 62-year-old woman with mild myopia presented to her local optometrist for a routine examination and was found to have intraocular pressure (IOP) of 30 mm Hg in both eyes and cupped nerves. She had a family history of glaucoma in her father. She was started on latanoprost in both eyes and was referred for a glaucoma evaluation. On initial evaluation, her IOP was 25 mm Hg in the right eye and 26 mm Hg in the left eye. Central corneal thickness measured 592 µm in the right eye and 581 µm in the left eye...
July 1, 2023: Journal of Cataract and Refractive Surgery
https://read.qxmd.com/read/37321374/rethinking-prophylactic-laser-peripheral-iridotomy-in-primary-angle-closure-suspects-a-review
#5
REVIEW
Theodoros Filippopoulos, John Danias, Efthymios Karmiris, Gordana Sunaric Mégevand, Douglas J Rhee, Gus Gazzard, Fotis Topouzis, Benjamin Xu
PURPOSE: To examine the generalizability, discuss limitations, and critically appraise recommendations on the management of primary angle-closure suspects (PACSs) that emerged as a result of recent randomized clinical trials challenging the widely accepted clinical practice of offering laser peripheral iridotomy (LPI) to PACS patients. To synthetize findings from these and other studies. DESIGN: Narrative review. SUBJECTS: Patients classified as PACS...
2023: Ophthalmology Glaucoma
https://read.qxmd.com/read/37302545/impact-of-glaucoma-medications-on-the-ocular-surface-and-how-ocular-surface-disease-can-influence-glaucoma-treatment
#6
JOURNAL ARTICLE
Miriam Kolko, Gus Gazzard, Christophe Baudouin, Sofie Beier, Françoise Brignole-Baudouin, Barbara Cvenkel, Fredrik Fineide, Anne Hedengran, Anton Hommer, Erik Jespersen, Elisabeth M Messmer, Rachna Murthy, Amy Gallant Sullivan, Andrew J Tatham, Tor Paaske Utheim, Marijke Vittrup, David A Sullivan
Glaucoma is a common disease with an increasing prevalence [1]. Ocular surface disease (OSD) is also common, and its prevalence is increasing [2,3], due in part to the adverse effects of topical glaucoma medications [4,5]. Given this glaucoma/OSD association, David A. Sullivan, MS, PhD (Boston, MA, USA) and Amy Gallant Sullivan (Paris, France) on behalf of the Tear Film & Ocular Surface Society (TFOS), and in collaboration with Miriam Kolko, MD, PhD (Copenhagen University Hospital & University of Copenhagen, Denmark), organized a one-day meeting which was held on Saturday, October 22, in Cernobbio, Italy...
June 9, 2023: Ocular Surface
https://read.qxmd.com/read/37095276/treatment-expectations-in-glaucoma-what-matters-most-to-patients
#7
JOURNAL ARTICLE
Atika Safitri, Evgenia Konstantakopoulou, Kuang Hu, Gus Gazzard
BACKGROUND/OBJECTIVES: Recent clinical trials in glaucoma have used patient-reported outcome measures (PROMs) of health-related quality of life to evaluate interventions. However, existing PROMs may not be sufficiently sensitive to capture changes in health status. This study aims to determine what really matters to patients by directly exploring their treatment expectations and preferences. SUBJECTS/METHODS: We conducted a qualitative study using one-to-one semi-structured interviews to elicit patients' preferences...
April 24, 2023: Eye
https://read.qxmd.com/read/36918628/clinical-risk-stratification-in-glaucoma
#8
REVIEW
Ali Poostchi, Alan Kastner, Evgenia Konstantakopoulou, Gus Gazzard, Hari Jayaram
Glaucoma is the leading cause of preventable sight loss in the United Kingdom and the provision of timely glaucoma care has been highlighted as a significant challenge in recent years. Following a recent high-profile investigation, The Healthcare Safety Investigation Branch recommended the validation of risk stratification models to safeguard the vision-related quality of life of glaucoma patients. There continues to be no nationally agreed evidence-based risk stratification model for glaucoma care across the United Kingdom...
March 14, 2023: Eye
https://read.qxmd.com/read/36813144/five-year-visual-field-outcomes-of-the-horizon-trial
#9
JOURNAL ARTICLE
Giovanni Montesano, Giovanni Ometto, Iqbal Ike K Ahmed, Pradeep Y Ramulu, David F Chang, David P Crabb, Gus Gazzard
PURPOSE: To compare visual field (VF) progression between glaucoma patients receiving cataract surgery alone (CS) or with a Hydrus microstent (CS-HMS). DESIGN: Post hoc analysis of VF data from the HORIZON multicenter randomized controlled trial. METHODS: A total of 556 patients with glaucoma and cataract were randomized 2:1 to either CS-HMS (369) or CS (187) and followed up for 5 years. VF was performed at 6 months and then every year after surgery...
February 21, 2023: American Journal of Ophthalmology
https://read.qxmd.com/read/36653163/differentiating-stages-of-functional-vision-loss-from-glaucoma-using-the-disc-damage-likelihood-scale-and-cup-disc-ratio
#10
RANDOMIZED CONTROLLED TRIAL
Heiko Philippin, Einoti Naino Matayan, Karin Marianne Knoll, Edith Macha, Sia Mbishi, Andrew Makupa, Cristóvão Daniel Matsinhe, Isac Vasco da Gama, Mário Jorge Monjane, Joyce Awum Ncheda, Francisco Alcides Francisco Mulobuana, Elisante Muna, Nelly Fopoussi Guylene, Gus Gazzard, Ana Patricia Marques, Peter Shah, David Macleod, William Makupa, Matthew J Burton
BACKGROUND: Glaucoma staging is critical for treatment planning but has rarely been tested in severe/end-stage disease. We compared the performance of the Disc Damage Likelihood Scale (DDLS) and cup:disc ratio (CDR) using a functional glaucoma staging system (GSS) as the reference standard. METHODS: Post hoc analysis of a randomised controlled trial at the Eye Department of Kilimanjaro Christian Medical Centre, Tanzania. Eligible participants (aged ≥18 years) with open-angle glaucoma, intraocular pressure (IOP) of >21 mm Hg, were randomised to timolol 0...
February 21, 2024: British Journal of Ophthalmology
https://read.qxmd.com/read/36621864/iridotomy-to-slow-progression-of-visual-field-loss-in-angle-closure-glaucoma
#11
REVIEW
Benjamin Rouse, Jimmy T Le, Gus Gazzard
BACKGROUND: Primary angle-closure glaucoma is a type of glaucoma associated with a physically obstructed anterior chamber angle. For example, contact between the iris and lens at the pupillary margin creates a pupillary block that increases resistance to aqueous outflow. Obstruction of the anterior chamber angle blocks drainage of fluids (aqueous humor) within the eye and may raise intraocular pressure (IOP). Elevated IOP is associated with glaucomatous optic nerve damage and visual field loss...
January 9, 2023: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/36565904/design-and-conduct-of-randomized-clinical-trials-evaluating-surgical-innovations-in-ophthalmology-a-systematic-review
#12
REVIEW
Augusto Azuara-Blanco, Aaron Carlisle, Matthew O'Donnell, Hari Jayaram, Gus Gazzard, Daniel F P Larkin, Louisa Wickham, Noemi Lois
PURPOSE: Surgical innovations are necessary to improve patient care. After an initial exploratory phase novel surgical technique should be compared with alternative options or standard care in randomized clinical trials (RCTs). However surgical RCTs have unique methodological challenges. Our study sought to investigate key aspects of the design, conduct and reporting of RCTs of novel surgeries. DESIGN: Systematic Review METHODS: The protocol was prospectively registered in PROSPERO (CRD42021253297)...
December 21, 2022: American Journal of Ophthalmology
https://read.qxmd.com/read/36122660/laser-in-glaucoma-and-ocular-hypertension-light-trial-six-year-results-of-primary-selective-laser-trabeculoplasty-versus-eye-drops-for-the-treatment-of-glaucoma-and-ocular-hypertension
#13
RANDOMIZED CONTROLLED TRIAL
Gus Gazzard, Evgenia Konstantakopoulou, David Garway-Heath, Mariam Adeleke, Victoria Vickerstaff, Gareth Ambler, Rachael Hunter, Catey Bunce, Neil Nathwani, Keith Barton
PURPOSE: The Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial has shown selective laser trabeculoplasty (SLT) to be clinically and cost-effective as a primary treatment of open-angle glaucoma (OAG) and ocular hypertension (OHT) at 3 years. This article reports health-related quality of life (HRQoL) and clinical effectiveness of initial treatment with SLT compared with intraocular pressure (IOP)-lowering eye drops after 6 years of treatment. DESIGN: Prospective, multicenter randomized controlled trial...
February 2023: Ophthalmology
https://read.qxmd.com/read/35725765/prevention-of-angle-closure-glaucoma-balancing-risk-and-benefit
#14
EDITORIAL
Paul J Foster, Wai Siene Ng, Winifred P Nolan, Luke Tanner, Gus Gazzard, Alex C Day, Roshini Sanders, Barny Foot, John F Salmon, Augusto Azuara-Blanco
No abstract text is available yet for this article.
June 20, 2022: Eye
https://read.qxmd.com/read/35701875/energy-dose-response-in-selective-laser-trabeculoplasty-a-review
#15
REVIEW
Nathan Radcliffe, Gus Gazzard, Thomas Samuelson, Peng Khaw, Xinghuai Sun, Tin Aung, Dennis Lam, Kuldev Singh, L Jay Katz, Michael Aronov, Zachary Sacks, Yoram Solberg, Richard Lindstrom, Michael Belkin
PRCIS: A literature review of selective laser trabeculoplasty (SLT) energy dose-response found no definitive relationship between intraocular pressure (IOP) reduction with respect to total or pulse energy, race, pigmentation, or application pattern. PURPOSE: SLT is a safe and effective treatment for lowering IOP. Although evidence is mounting for the advantage of its use as a first-line treatment for IOP reduction, the SLT procedures in use vary widely. The purpose of this literature review was to investigate whether there were any relationships between SLT energy and efficacy for lowering IOP in the published literature...
August 1, 2022: Journal of Glaucoma
https://read.qxmd.com/read/35594917/adverse-effects-and-safety-in-glaucoma-patients-agreement-on-clinical-trial-outcomes-for-reports-on-eye-drops-asgard-a-delphi-consensus-statement
#16
JOURNAL ARTICLE
Anna-Sophie Thein, Anne Hedengran, Augusto Azuara-Blanco, Reiko Arita, Barbara Cvenkel, Gus Gazzard, Steffen Heegaard, Cintia S de Paiva, Goran Petrovski, Verena Prokosch-Willing, Tor P Utheim, Gianni Virgili, Miriam Kolko
PURPOSE: The purpose of this study is to establish consensus among experts on outcomes and methods to be used in clinical trials to assess adverse effects of anti-glaucomatous eye drops. DESIGN: Modified Delphi method. METHODS: Clinical experts from Europe, North America, South America, the Middle East, and Asia were invited to participate in 2 sequential web-based surveys administered from June 27 to August 29, 2021. A total of 91 clinical experts were invited to participate...
September 2022: American Journal of Ophthalmology
https://read.qxmd.com/read/35568384/is-selective-laser-trabeculoplasty-shifting-the-glaucoma-treatment-paradigm-in-developing-countries
#17
EDITORIAL
Evgenia Konstantakopoulou, Gus Gazzard
No abstract text is available yet for this article.
September 2022: British Journal of Ophthalmology
https://read.qxmd.com/read/35534178/validation-of-the-rcophth-and-ukegs-glaucoma-risk-stratification-tool-glauc-strat-fast
#18
JOURNAL ARTICLE
Evgenia Konstantakopoulou, Alan Kastner, Gus Gazzard, Hari Jayaram
BACKGROUND/AIMS: The aim of this study was to validate the Glaucoma Risk Stratification Tool (GLAUC-STRAT-fast) currently recommended by the Royal College of Ophthalmologists for the risk stratification of patients with glaucoma in the UK National Health Service Hospital Eye Service. METHODS: GLAUC-STRAT fast was applied to the LiGHT trial participants by risk-stratifying the worse eye of each patient at baseline and after 3 years of treatment. Metrics of disease severity or treatment intensity used for the validation were: increased number of monitoring visits or treatment escalations; needing a trabeculectomy; a reduction of >2 dB in visual field mean deviation (VF MD) during the monitoring period; identification of rapid VF loss on total (TD) and/or pattern deviation (PD)...
May 9, 2022: British Journal of Ophthalmology
https://read.qxmd.com/read/35086806/intraocular-pressure-and-diurnal-fluctuation-of-open-angle-glaucoma-and-ocular-hypertension-a-baseline-report-from-the-light-china-trial-cohort
#19
JOURNAL ARTICLE
Yangfan Yang, Xinyi Zhang, Zidong Chen, Yifan Wei, Qiaona Ye, Yanmei Fan, Neil Nathwani, Gus Gazzard, Minbin Yu
AIMS: To report the baseline intraocular pressure (IOP) characteristics and its diurnal fluctuation in the Laser in Glaucoma and Ocular Hypertension China cohort. METHODS: 622 primary open-angle glaucoma (POAG) patients and 149 ocular hypertension (OHT) patients were recruited at Zhongshan Ophthalmic Center from 2015 to 2019. Standardised ocular examinations were performed including IOP measurement using the Goldmann applanation tonometer. Daytime phasing IOP was recorded at 8:00, 10:00, 11:30, 14:30, 17:00 hour...
January 27, 2022: British Journal of Ophthalmology
https://read.qxmd.com/read/34675001/european-glaucoma-society-terminology-and-guidelines-for-glaucoma-5th-edition
#20
JOURNAL ARTICLE
(no author information available yet)
The only time is now. Every "now" is unique. Responsible persons ask themselves, "How can I act well now?" The answers will differ for every person, because just as every situation is unique, so is every person different from every other person. But surely there must be some algorithm that will assist us in coming to the right answer. Unfortunately, no, for there is no right answer. There is only an answer that is as appropriate as we can conclude at that moment in that situation. No written guidelines can apply appropriately to every unique situation...
June 2021: British Journal of Ophthalmology
keyword
keyword
20491
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.